January 6, 2026, Chiyoda-ku, Tokyo — PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jun Minamitani) has successfully developed a novel synthetic peptide called “IL-15 alternative peptide” which is functionally equivalent to recombinant interleukin 15 (IL-15). This product will be on the market in December 2025. [Read more…]
How To (Potentially) Avoid Back Pain Surgery with Stem Cells
According to the National Institute of Neurological Disorders and Stroke, 80% of Americans will have at least one episode of lower (or lumbar) back pain in their lifetimes. Discomfort or pain in the cervical and thoracic regions is common as well, with an estimated one-third of Americans living with pain at any given time. For much of human history, back pain treatment consisted of home remedies, massage, cold and heat therapies, and rest – but not much more.
In this article:
Induced Pluripotent Stem Cell (iPSC) Industry Trends Dominating in 2026
Induced pluripotent stem cells (iPS cells or iPSCs) are laboratory-made pluripotent stem cells that are produced using non-controversial adult cells. They are derived from somatic cells through reprogramming and turning on the expression of specific pluripotency genes. This reprogramming can be achieved using different techniques with varying efficiencies. [Read more…]
The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered “virtual hearts”
New CARDIOVERSE project combines AI, stem cells, and genetic variation to predict drug safety before human trials
BAR HARBOR, Maine, Dec. 8, 2025 — Developing new drugs is one of the riskiest and most expensive endeavors in science. Today, The Jackson Laboratory (JAX) announced a bold initiative to improve that trajectory, powered by an up to $30 million contract from the Advanced Research Projects Agency for Health (ARPA-H) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. CATALYST is led by ARPA-H Health Science Futures Mission Office Acting Deputy Director Andy Kilianski, Ph.D.
[Read more…]
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia
December 08, 2025, Silver Spring, MD (U.S. FDA) — The U.S. Food and Drug Administration announced that it has approved Omisirge (omidubicel-onlv), the first hematopoietic stem cell transplant (HSCT) therapy to treat patients with severe aplastic anemia (SAA). Omisirge is indicated for adults and pediatric patients 12 years and older with hematologic malignancies and now is approved for adults and pediatric patients six years and older with SAA following reduced intensity conditioning and for whom a compatible donor is not available. [Read more…]
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 334
- Next Page »